Osteonecrosis of the jaws produced by sunitiniba systematic review

  1. Carmen Vallina 1
  2. Lucía Ramírez Martínez Acitores 2
  3. Jesús Torres García Denche 3
  4. Elisabeth Casañas Gil 4
  5. Gonzalo Hernández Vallejo 5
  6. Rosa Mª López-Pintor Muñoz 6
  1. 1 DDS, Oral Medicine Postgraduate. Department of Dental Clinical Specialties. School of Dentistry. Complutense University, Madrid, Spain
  2. 2 DDS, PhD Student, Oral Medicine Postgraduate. Department of Dental Clinical Specialties. School of Dentistry. Complutense University, Madrid, Spain
  3. 3 DDS, PhD, Professor. Department of Dental Clinical Specialties. School of Dentistry. Complutense University, Madrid, Spain
  4. 4 DDS, PhD, Researcher, Oral Medicine Postgraduate. Department of Dental Clinical Specialties. School of Dentistry. Complutense University, Madrid, Spain
  5. 5 MD, DDS, PhD, Professor, Director Specialty in Oral Medicine. Department of Dental Clinical Specialties. School of Dentistry. Complutense University, Madrid, Spain
  6. 6 DDS, PhD, Associate Professor, Co-director Speciality in Oral Medicine. Department of Dental Clinical Specialties. School of Dentistry. Complutense University, Madrid, Spain
Mostrar afiliaciones +
Revista:
Medicina oral, patología oral y cirugía bucal. Ed. inglesa

ISSN: 1698-6946

Año de publicación: 2019

Volumen: 24

Número: 3

Páginas: 2

Tipo: Artículo

DOI: 10.4317/MEDORAL.22858 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Medicina oral, patología oral y cirugía bucal. Ed. inglesa

Resumen

Tyrosine kinase receptor family is involved in tumor growth, pathological angiogenesis and the progression (metastasis) of cancer. Sunitinib (Sutent®) inhibits members of the tyrosine kinase receptor family affecting the induction of angiogenesis and tumor progression. It is not clear if sunitinib increases the risk of osteonecrosis of the jaws (ONJ). The aim of this study was to carry out a systematic review about ONJ related to sunitinib, describing existing cases and possible associated risk factors. The PubMed/MEDLINE and Cochrane Library databases were searched without date restriction up to September 2018. We included prospective and retrospective observational studies, cross-sectional studies, clinical cases and series of cases, involving only human subjects. The methodological quality of the studies was assessed using The Joanna Briggs Institute (JBI) and Newcastle-Ottawa tools. A total of 13 studies fulfilled our inclusion criteria of which 7 were clinical cases, 5 case series and a retrospective study. All the articles were published between 2009 and 2018. Of the 102 patients treated with sunitinib analyzed in this study, 58 developed ONJ, being or having been treated with sunitinib and bisphosphonates or exclusively with sunitinib. In this systematic review, we found an increase of ONJ in patients who are medicated with other drugs different than bisphosphonates and denosumab. It is necessary that dentists, oral and maxillofacial surgeons as well as oncologists know the risk of ONJ that these antiresorptive drugs could have. There is a need to continue researching in this field with the aim of an increasing knowledge in this area and creating an adequate protocol of action for this population.

Referencias bibliográficas

  • Khan, AA,Morrison, A,Hanley, DA,Felsenberg, D,McCauley, LK,O'Ryan, F. (2015). Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 30. 3-23
  • Bagan, J,Peydró, A,Calvo, J,Leopoldo, M,Jiménez, Y,Bagan, L. (2016). Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. Oral Dis. 22. 324
  • Ramírez, L,López-Pintor, RM,Casañas, E,Arriba, L,Hernández, G. (2015). New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws. Oral Health Prev Dent. 13. 385
  • Hoefert, S,Eufinger, H. (2010). Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 110. 463
  • Goodman, VL,Rock, EP,Dagher, R,Ramchandani, RP,Abraham, S,Gobburu, JV. (2007). Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma. Clin Cancer Res. 13. 1367
  • Beuselinck, B,Wolter, P,Karadimou, A,Elaidi, R,Dumez, H,Rogiers, A. (2012). Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer. 107. 1665
  • Fleissig, Y,Regev, E,Lehman, H. (2012). Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 113. 1-3
  • (2011). Medicines and Healthcare products Regulatory Agency Gov. UK.
  • Nicolatou-Galitis, O,Migkou, M,Psyrri, A,Bamias, A,Pectasides, D,Economopoulos, T. (2012). Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol. 113. 234
  • Moher D, LA,Tetzlaff, J,Altman, DG. (2009). The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 6. 1000097
  • Ruggiero, SL,Dodson, TB,Fantasia, J,Goodday, R,Aghaloo, T,Mehrotra, B. (2014). American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 72. 1938
  • Moola, S,Munn, Z,Tufanaru, C,Aromataris, E,Sears, K,Raluca, S. (2017). Chapter 7: Systematic reviews of etiology and risk. Joanna Briggs Institute Reviewer's Manual.
  • Wells, GA,Shea, B,O'Connel, D,Peterson, J,Welch, V,Losos, M. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses.
  • Ashrafi, F,Derakhshandeh, A,Movahedian, B,Moghaddas, A. (2017). Osteonecrosis of the Jaws in Patient Received Bisphosphonates and Sunitinib Separately: A Case Report. J Res Pharm Pract. 6. 182
  • Agrillo, A,Nastro Siniscalchi, E,Facchini, A,Filiaci, F,Ungari, C. (2012). Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports. Eur Rev Med Pharmacol Sci. 16. 952
  • Balmor, GR,Yarom, N,Weitzen, R. (2012). Drug-induced palate osteonecrosis following nasal surgery. Isr Med Assoc J. 14. 193
  • Bozas, G,Roy, A,Ramasamy, V,Maraveyas, A. (2010). Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. Onkologie. 33. 321
  • Koch, FP,Walter, C,Hansen, T,Jäger, E,Wagner, W. (2011). Osteonecrosis of the jaw related to sunitinib. J Oral Maxillofac Surg. 15. 63
  • Brunello, A,Saia, G,Bedogni, A,Scaglione, D,Basso, U. (2009). Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone. 44. 173
  • Mahedi Mohamed, AH,Nielsen, CE,Schiodt, M. (2018). Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol. 125. 157
  • Fusco, V,Porta, C,Saia, G,Paglino, C,Bettini, G,Scoletta, M. (2015). Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: Results of an Italian multicenter study and review of the literature. Clin Genitourin Cancer. 13. 287
  • Smidt-Hansen, T,Folkmar, TB,Fode, K,Agerbaek, M,Donskov, F. (2013). Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg. 71. 1532
  • Christodoulou, C,Pervena, A,Klouvas, G,Galani, E,Falagas, ME,Tsakalos, G. (2009). Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology. 76. 209
  • McKay, RR,Lin, X,Perkins, JJ,Heng, DY,Simantov, R,Choueiri, TK. (2014). Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol. 66. 502
  • Ripamonti, CI,Lucchesi, M,Giusti, R. (2016). Prevention and management of osteonecrosis of the jaw secondary to bone-targeted therapy in patients with kidney cancer. Curr Opin Support Palliat Care. 10. 273
  • Troeltzsch, M,Woodlock, T,Kriegelstein, S,Steiner, T,Messlinger, K,Troeltzsch, M. (2012). Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc. 78. 85
  • Martins, AS,Correia, JA,Salvado, F,Caldas, C,Santos, N,Capelo, A. (2017). Relevant factors for treatment outcome and time to healing in medication related osteonecrosis of the jaws - A retrospective cohort study. J Craniomaxillofac Surg. 45. 1736
  • Marx, RE,Sawatari, Y,Fortin, M,Broumand, V. (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 63. 1567
Fuente de los datos: Dialnet